Asset
DENIFANSTAT
SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07216313 | phase1 | completed | 2025-09-30 | 2025-10-20 | Sagimet Biosciences Inc. | A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants |
| NCT02223247 | phase1 | completed | 2013-11-01 | 2017-06-01 | Sagimet Biosciences Inc. | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors |
| NCT06594523 | phase3 | withdrawn | 2025-03-01 | 2030-12-01 | Sagimet Biosciences Inc. | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis |
| NCT06692283 | phase3 | withdrawn | 2025-03-01 | 2026-06-01 | Sagimet Biosciences Inc. | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH |
| NCT05835180 | phase1 | completed | 2023-05-01 | 2023-12-18 | Sagimet Biosciences Inc. | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function |
FDA applications (0)
This company has no applications containing this asset.